Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Die Ophthalmologie
Erschienen in: Die Ophthalmologie 2/2022

06.04.2022 | Leitlinien, Stellungnahmen und Empfehlungen

Statement of the Professional Association of Ophthalmologists in Germany (BVA), the German Society of Ophthalmology (DOG) and the German Retina Society (RG) on central serous chorioretinopathy

Status 18 October 2021

verfasst von: Professional Association of German Ophthalmologists (Berufsverband der Augenärzte Deutschlands e. V., BVA), German Society of Ophthalmology (Deutsche Ophthalmologische Gesellschaft, DOG), German Retina Society e. V. (Retinologische Gesellschaft e. V., RG)

Erschienen in: Die Ophthalmologie | Sonderheft 2/2022

Einloggen, um Zugang zu erhalten

Excerpt

  • Central serous chorioretinopathy (CSC) is a unilateral or bilateral macular disease that is initially associated with choroidal thickening and the accumulation of subretinal fluid (SRF).
…
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Alkin Z, Osmanbasoglu OA, Ozkaya A, Karatas G, Yazici AT (2013) Topical nepafenac in treatment of acute central serous chorioretinopathy. Med Hypothesis Discov Innov Ophthalmol 2:96–101PubMedPubMedCentral
2.
Ayata A, Tatlipinar S, Kar T, Unal M, Ersanli D, Bilge AH (2009) Near-infrared and short-wavelength autofluorescence imaging in central serous chorioretinopathy. Br J Ophthalmol 93:79–82PubMedCrossRef
3.
Azad AD, Zhou M, Afshar AR, Bakri SJ, Pershing S (2021) Systemic corticosteroid use after central serous chorioretinopathy diagnosis. Ophthalmology 128:121–129PubMedCrossRef
4.
Bae SH, Heo JW, Kim C, Kim TW, Lee JY, Song SJ, Park TK, Moon SW, Chung H (2011) A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy. Am J Ophthalmol 152:784–792.e2PubMedCrossRef
5.
Battaglia Parodi M, Da Pozzo S, Ravalico G (2003) Photodynamic therapy in chronic central serous chorioretinopathy. Retina 23:235–237PubMedCrossRef
6.
Bonini Filho MA, de Carlo TE, Ferrara D, Adhi M, Baumal CR, Witkin AJ, Reichel E, Duker JS, Waheed NK (2015) Association of choroidal neovascularization and central serous chorioretinopathy with optical coherence tomography angiography. JAMA Ophthalmol 133:899–906PubMedCrossRef
7.
Borrelli E, Sarraf D, Freund KB, Sadda SR (2018) OCT angiography and evaluation of the choroid and choroidal vascular disorders. Prog Retin Eye Res 67:30–55PubMedCrossRef
8.
Bousquet E, Beydoun T, Rothschild P‑R, Bergin C, Zhao M, Batista R, Brandely M‑L, Couraud B, Farman N, Gaudric A et al (2015) Spironolactone for nonresolving central serous chorioretinopathy. Retina 35:2505–2515PubMedPubMedCentralCrossRef
9.
10.
Bujarborua D (2001) Long-term follow-up of idiopathic central serous chorioretinopathy without laser. Acta Ophthalmol Scand 79:417–421PubMedCrossRef
11.
Bujarborua D, Chatterjee S, Choudhury A, Bori G, Sarma AK (2005) Fluorescein angiographic features of asymptomatic eyes in central serous chorioretinopathy. Retina 25:422–429PubMedCrossRef
12.
Bujarborua D, Nagpal PN, Deka M (2010) Smokestack leak in central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 248:339–351PubMedCrossRef
13.
Caccavale A, Romanazzi F, Imparato M, Negri A, Morano A, Ferentini F (2010) Low-dose aspirin as treatment for central serous chorioretinopathy. Clin Ophthalmol 4:899–903PubMedPubMedCentralCrossRef
14.
Cakir B, Reich M, Lang S, Bühler A, Ehlken C, Grundel B, Stech M, Reichl S, Stahl A, Böhringer D et al (2019) OCT angiography of the choriocapillaris in central serous chorioretinopathy: a quantitative subgroup analysis. Ophthalmol Ther 8:75–86PubMedPubMedCentralCrossRef
15.
Chan W‑M, Lam DSC, Lai TYY, Tam BSM, Liu DTL, Chan CKM (2003) Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol 87:1453–1458PubMedPubMedCentralCrossRef
16.
Chan W‑M, Lai TYY, Lai RYK, Liu DTL, Lam DSC (2008) Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology 115:1756–1765PubMedCrossRef
17.
Chen S‑N, Hwang J‑F, Tseng L‑F, Lin C‑J (2008) Subthreshold diode micropulse photocoagulation for the treatment of chronic central serous chorioretinopathy with juxtafoveal leakage. Ophthalmology 115:2229–2234PubMedCrossRef
18.
19.
Cheng C‑K, Chang C‑K, Peng C‑H (2017) Comparison of photodynamic therapy using half-dose of verteporfin or half-fluence of laser light for the treatment of chronic central serous chorioretinopathy. Retina 37:325–333PubMedCrossRef
20.
Cheung CMG, Lee WK, Koizumi H, Dansingani K, Lai TYY, Freund KB (2019) Pachychoroid disease. Eye (Lond) 33:14–33CrossRef
21.
22.
Chuang EL, Sharp DM, Fitzke FW, Kemp CM, Holden AL, Bird AC (1987) Retinal dysfunction in central serous retinopathy. Eye (Lond) 1(1):120–125CrossRef
23.
Chung Y‑R, Seo EJ, Lew HM, Lee KH (2013) Lack of positive effect of intravitreal bevacizumab in central serous chorioretinopathy: meta-analysis and review. Eye (Lond) 27:1339–1346CrossRef
24.
25.
26.
Delori FC, Dorey CK, Staurenghi G, Arend O, Goger DG, Weiter JJ (1995) In vivo fluorescence of the ocular fundus exhibits retinal pigment epithelium lipofuscin characteristics. Invest Ophthalmol Vis Sci 36:718–729PubMed
27.
Desai UR, Alhalel AA, Campen TJ, Schiffman RM, Edwards PA, Jacobsen GR (2003) Central serous chorioretinopathy in African Americans. J Natl Med Assoc 95:553–559PubMedPubMedCentral
28.
van Dijk EHC, Fauser S, Breukink MB, Blanco-Garavito R, Groenewoud JMM, Keunen JEE, Peters PJH, Dijkman G, Souied EH, MacLaren RE et al (2018) Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy. Ophthalmology 125:1547–1555PubMedCrossRef
29.
Ficker L, Vafidis G, While A, Leaver P (1988) Long-term follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol 72:829–834PubMedPubMedCentralCrossRef
30.
Fok ACT, Chan PPM, Lam DSC, Lai TYY (2011) Risk factors for recurrence of serous macular detachment in untreated patients with central serous chorioretinopathy. Ophthalmic Res 46:160–163PubMedCrossRef
31.
Forooghian F, Meleth AD, Cukras C, Chew EY, Wong WT, Meyerle CB (2011) Finasteride for chronic central serous chorioretinopathy. Retina 31:766–771PubMedPubMedCentralCrossRef
32.
French DD, Margo CE (2010) Central serous chorioretinopathy and phosphodiesterase‑5 inhibitors: a case-control postmarketing surveillance study. Retina 30:271–274PubMedCrossRef
33.
Gäckle HC, Lang GE, Freissler KA, Lang GK (1998) Central serous chorioretinopathy. Clinical, fluorescein angiography and demographic aspects. Ophthalmologe 95:529–533PubMedCrossRef
34.
de Gasparo M, Joss U, Ramjoué HP, Whitebread SE, Haenni H, Schenkel L, Kraehenbuehl C, Biollaz M, Grob J, Schmidlin J (1987) Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 240:650–656PubMed
35.
Gass JD (1967) Pathogenesis of disciform detachment of the neuroepithelium. Am J Ophthalmol 63:1–139
36.
Gass JD, Little H (1995) Bilateral bullous exudative retinal detachment complicating idiopathic central serous chorioretinopathy during systemic corticosteroid therapy. Ophthalmology 102:737–747PubMedCrossRef
37.
38.
Haimovici R, Rumelt S, Melby J (2003) Endocrine abnormalities in patients with central serous chorioretinopathy. Ophthalmology 110:698–703PubMedCrossRef
39.
Heinrich MR (1974) Central serous retinopathy and alpha-blockaders. Bull Soc Ophtalmol Fr 74:681–683PubMed
40.
Ho M, Lai FHP, Ng DSC, Iu LPL, Chen LJ, Mak ACY, Yip Y, Cheung C, Young AL, Brelen M (2021) Analysis of choriocapillaris perfusion and choroidal layer changes in patients with chronic central serous chorioretinopathy randomised to micropulse laser or photodynamic therapy. Br J Ophthalmol 105:555–560PubMedCrossRef
41.
Hu J, Qu J, Li M, Sun G, Piao Z, Liang Z, Yao Y, Sadda S, Zhao M (2021) Optical coherence tomography angiography-guided photodynamic therapy for acute central serous chorioretinopathy. Retina 41:189–198PubMedCrossRef
42.
Iacono P, Battaglia PM, Papayannis A, La Spina C, Varano M, Bandello F (2015) Acute central serous chorioretinopathy: a correlation study between fundus autofluorescence and spectral-domain OCT. Graefes Arch Clin Exp Ophthalmol 253:1889–1897PubMedCrossRef
43.
Iida T, Yannuzzi LA, Spaide RF, Borodoker N, Carvalho CA, Negrao S (2003) Cystoid macular degeneration in chronic central serous chorioretinopathy. Retina 23:1–7 (quiz 137–138)PubMedCrossRef
44.
Jain AK, Kaines A, Schwartz S (2010) Bilateral central serous chorioretinopathy resolving rapidly with treatment for obstructive sleep apnea. Graefes Arch Clin Exp Ophthalmol 248:1037–1039PubMedCrossRef
45.
de Jong EK, Breukink MB, Schellevis RL, Bakker B, Mohr JK, Fauser S, Keunen JEE, Hoyng CB, den Hollander AI, Boon CJF (2015) Chronic central serous chorioretinopathy is associated with genetic variants implicated in age-related macular degeneration. Ophthalmology 122:562–570PubMedCrossRef
46.
Katsimpris JM, Pournaras CJ, Sehgelmeble CW, Petropoulos IK (2007) Severe bilateral central serous chorioretinopathy in a black patient: 16 years follow-up. Graefes Arch Clin Exp Ophthalmol 245:460–463PubMedCrossRef
47.
48.
Kim KS, Lee WK, Lee SB (2014) Half-dose photodynamic therapy targeting the leakage point on the fluorescein angiography in acute central serous chorioretinopathy: a pilot study. Am J Ophthalmol 157:366–373.e1PubMedCrossRef
49.
Kitaya N, Nagaoka T, Hikichi T, Sugawara R, Fukui K, Ishiko S, Yoshida A (2003) Features of abnormal choroidal circulation in central serous chorioretinopathy. Br J Ophthalmol 87:709–712PubMedPubMedCentralCrossRef
50.
Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP (2008) The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980–2002. Ophthalmology 115:169–173PubMedCrossRef
51.
Koss MJ, Beger I, Koch FH (2012) Subthreshold diode laser micropulse photocoagulation versus intravitreal injections of bevacizumab in the treatment of central serous chorioretinopathy. Eye (Lond) 26:307–314CrossRef
52.
53.
Lai TYY, Staurenghi G, Lanzetta P, Holz FG, Melissa Liew SH, Desset-Brethes S, Staines H, Hykin PG, MINERVA study group (2018) Efficacy and safety of ranibizumab for the treatment of choroidal neovascularization due to uncommon cause: twelve-month results of the MINERVA study. Retina 38(8):1464–1477. https://​doi.​org/​10.​1097/​IAE.​0000000000001744​CrossRefPubMed
54.
Lainscak M, Pelliccia F, Rosano G, Vitale C, Schiariti M, Greco C, Speziale G, Gaudio C (2015) Safety profile of mineralocorticoid receptor antagonists: spironolactone and eplerenone. Int J Cardiol 200:25–29PubMedCrossRef
55.
Lavinsky D, Sramek C, Wang J, Huie P, Dalal R, Mandel Y, Palanker D (2014) Subvisible retinal laser therapy: titration algorithm and tissue response. Retina 34:87–97PubMedCrossRef
56.
57.
Lee H, Lee J, Chung H, Kim HC (2016) Baseline spectral domain optical coherence tomographic hyperreflective foci as a predictor of visual outcome and recurrence for central serous chorioretinopathy. Retina 36:1372–1380PubMedCrossRef
58.
Lim JI, Spee C, Hinton DR (2010) A comparison of hypoxia-inducible factor-alpha in surgically excised neovascular membranes of patients with diabetes compared with idiopathic epiretinal membranes in nondiabetic patients. Retina 30:1472–1478PubMedPubMedCentralCrossRef
59.
Lipowski ZJ, Kiriakos RZ (1971) Psychosomatic aspects of central serous retinopathy. A review and case report. Psychosomatics 12:398–401PubMedCrossRef
60.
Liu B, Deng T, Zhang J (2016) Risk factors for central serous chorioretinopathy: a systematic review and meta-analysis. Retina 36:9–19PubMedCrossRef
61.
Lotery A, Sivaprasad S, O’Connell A, Harris RA, Culliford L, Ellis L, Cree A, Madhusudhan S, Behar-Cohen F, Chakravarthy U et al (2020) Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. Lancet 395:294–303PubMedCrossRef
62.
Ma J, Meng N, Xu X, Zhou F, Qu Y (2014) System review and meta-analysis on photodynamic therapy in central serous chorioretinopathy. Acta Ophthalmol 92:e594–e601PubMedCrossRef
63.
Maruko I, Iida T, Sugano Y, Ojima A, Ogasawara M, Spaide RF (2010) Subfoveal choroidal thickness after treatment of central serous chorioretinopathy. Ophthalmology 117:1792–1799PubMedCrossRef
64.
65.
Matsumoto H, Kishi S, Otani T, Sato T (2008) Elongation of photoreceptor outer segment in central serous chorioretinopathy. Am J Ophthalmol 145:162–168PubMedCrossRef
66.
Meyerle CB, Freund KB, Bhatnagar P, Shah V, Yannuzzi LA (2007) Ketoconazole in the treatment of chronic idiopathic central serous chorioretinopathy. Retina 27:943–946PubMedCrossRef
67.
Mohabati D, van Rijssen TJ, van Dijk EH, Luyten GP, Missotten TO, Hoyng CB, Yzer S, Boon CJ (2018) Clinical characteristics and long-term visual outcome of severe phenotypes of chronic central serous chorioretinopathy. Clin Ophthalmol 12:1061–1070PubMedPubMedCentralCrossRef
68.
Mohabati D, Hoyng CB, Yzer S, Boon CJF (2020a) Clinical characteristics and outcome of posterior cystoid macular degeneration in chronic central serous chorioretinopathy. Retina 40:1742–1750PubMedCrossRef
69.
Mohabati D, Boon CJF, Yzer S (2020b) Risk of recurrence and transition to chronic disease in acute central serous chorioretinopathy. Clin Ophthalmol 14:1165–1175PubMedPubMedCentralCrossRef
70.
Nicholson B, Noble J, Forooghian F, Meyerle C (2013) Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol 58:103–126PubMedPubMedCentralCrossRef
71.
72.
Nicolò M, Zoli D, Musolino M, Traverso CE (2012) Association between the efficacy of half-dose photodynamic therapy with indocyanine green angiography and optical coherence tomography findings in the treatment of central serous chorioretinopathy. Am J Ophthalmol 153:474–480.e1PubMedCrossRef
73.
Nielsen JS, Jampol LM (2011) Oral mifepristone for chronic central serous chorioretinopathy. Retina 31:1928–1936PubMedCrossRef
74.
O’Keefe JH, Abuissa H, Pitt B (2008) Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS. Diabetes Obes Metab 10:492–497PubMedCrossRef
75.
Park D‑G, Jeong S, Noh D, Sagong M (2021) Optimal fluence rate of photodynamic therapy for chronic central serous chorioretinopathy. Br J Ophthalmol 105:844–849PubMedCrossRef
76.
77.
Peiretti E, Ferrara DC, Caminiti G, Mura M, Hughes J (2015) Choroidal neovascularization in caucasian patients with longstanding central serous chorioretinopathy. Retina 35:1360–1367PubMedCrossRef
78.
Piccolino FC, De La Longrais RR, Manea M, Cicinelli S (2008) Posterior cystoid retinal degeneration in central serous chorioretinopathy. Retina 28:1008–1012PubMedCrossRef
79.
Pichi F, Carrai P, Ciardella A, Behar-Cohen F, Nucci P, Central Serous Chorioretinopathy Study Group (2017) Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy. Int Ophthalmol 37(5):1115–1125PubMedCrossRef
80.
Pikkel J, Beiran I, Ophir A, Miller B (2002) Acetazolamide for central serous retinopathy. Ophthalmology 109:1723–1725PubMedCrossRef
81.
Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R, EPHESUS Investigators (2008) Serum potassium and clinical outcomes in the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS). Circulation 118:1643–1650PubMedCrossRef
82.
Quaranta-El Maftouhi M, El Maftouhi A, Eandi CM (2015) Chronic central serous chorioretinopathy imaged by optical coherence tomographic angiography. Am J Ophthalmol 160:581–587.e1PubMedCrossRef
83.
Rabiolo A, Bandello F (2020) Eplerenone is not superior to placebo for chronic central serous chorioretinopathy. Lancet 395:252–253PubMedCrossRef
84.
Rahbani-Nobar MB, Javadzadeh A, Ghojazadeh L, Rafeey M, Ghorbanihaghjo A (2011) The effect of helicobacter pylori treatment on remission of idiopathic central serous chorioretinopathy. Mol Vis 17:99–103PubMedPubMedCentral
85.
Rahimy E, Pitcher JD, Hsu J, Adam MK, Shahlaee A, Samara WA, Vander JF, Kaiser RS, Chiang A, Spirn MJ et al (2018) A randomized double-blind placebo-control pilot study of eplerenone for the treatment of central serous chorioretinopathy (ECSELSIOR). Retina 38(5):962–969PubMedCrossRef
86.
Reibaldi M, Cardascia N, Longo A, Furino C, Avitabile T, Faro S, Sanfilippo M, Russo A, Uva MG, Munno F et al (2010) Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial. Am J Ophthalmol 149:307–315.e2PubMedCrossRef
87.
van Rijssen TJ, van Dijk EHC, Dijkman G, Boon CJF (2018) Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy. Graefes Arch Clin Exp Ophthalmol 256:1395–1402PubMedPubMedCentralCrossRef
88.
van Rijssen TJ, van Dijk EHC, Yzer S, Ohno-Matsui K, Keunen JEE, Schlingemann RO, Sivaprasad S, Querques G, Downes SM, Fauser S et al (2019a) Central serous chorioretinopathy: towards an evidence-based treatment guideline. Prog Retin Eye Res 73:100770PubMedCrossRef
89.
van Rijssen TJ, van Dijk EHC, Scholz P, Breukink MB, Blanco-Garavito R, Souied EH, Keunen JEE, MacLaren RE, Querques G, Fauser S et al (2019b) Focal and diffuse chronic central serous chorioretinopathy treated with half-dose photodynamic therapy or subthreshold micropulse laser: PLACE trial report no. 3. Am J Ophthalmol 205:1–10PubMedCrossRef
90.
van Rijssen TJ, van Dijk EHC, Scholz P, Breukink MB, Dijkman G, Peters PJH, Tsonaka R, MacLaren RE, Downes SM, Fauser S et al (2020) Crossover to photodynamic therapy or micropulse laser after failure of primary treatment of chronic central serous chorioretinopathy: the REPLACE trial. Am J Ophthalmol 216:80–89PubMedCrossRef
91.
van Rijssen TJ, van Dijk EHC, Scholz P, Breukink MB, Dijkman G, Peters PJH, Tsonaka R, Keunen JEE, MacLaren RE, Hoyng CB et al (2021) Long-term follow-up of chronic central serous chorioretinopathy after successful treatment with photodynamic therapy or micropulse laser. Acta Ophthalmol. https://​doi.​org/​10.​1111/​aos.​14775CrossRefPubMedPubMedCentral
92.
Robertson DM, Ilstrup D (1983) Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy. Am J Ophthalmol 95:457–466PubMedCrossRef
93.
Rouvas A, Stavrakas P, Theodossiadis PG, Stamatiou P, Milia M, Giannakaki E, Datseris I (2012) Long-term results of half-fluence photodynamic therapy for chronic central serous chorioretinopathy. Eur J Ophthalmol 22(3):417–422PubMedCrossRef
94.
Sacconi R, Baldin G, Carnevali A, Querques L, Rabiolo A, Marchini G, Bandello F, Querques G (2018) Response of central serous chorioretinopathy evaluated by multimodal retinal imaging. Eye (Lond) 32:734–742CrossRef
95.
Sacconi R, Borrelli E, Querques G (2020) Eplerenone for chronic central serous chorioretinopathy. Lancet 396:1556PubMedCrossRef
96.
Sadda SR (2020) Lack of efficacy of eplerenone for treatment of active central serous chorioretinopathy. Eye (Lond) 34:1489–1490CrossRef
97.
Salehi M, Wenick AS, Law HA, Evans JR, Gehlbach P (2015) Interventions for central serous chorioretinopathy: a network meta-analysis. Cochrane Database Syst Rev 12:CD11841
98.
Scholz P, Altay L, Fauser S (2017) A review of subthreshold micropulse laser for treatment of macular disorders. Adv Ther 34:1528–1555PubMedPubMedCentralCrossRef
99.
Schubert C, Pryds A, Zeng S, Xie Y, Freund KB, Spaide RF, Merriam JC, Barbazetto I, Slakter JS, Chang S et al (2014) Cadherin 5 is regulated by corticosteroids and associated with central serous chorioretinopathy. Hum Mutat 35:859–867PubMedPubMedCentralCrossRef
100.
Schwartz R, Habot-Wilner Z, Martinez MR, Nutman A, Goldenberg D, Cohen S, Shulman S, Guzner-Gur H, Loewenstein A, Goldstein M (2017) Eplerenone for chronic central serous chorioretinopathy—a randomized controlled prospective study. Acta Ophthalmol 95(7):e610–e618. https://​doi.​org/​10.​1111/​aos.​13491CrossRefPubMed
101.
Senturk F, Karacorlu M, Ozdemir H, Karacorlu SA, Uysal O (2011) Microperimetric changes after photodynamic therapy for central serous chorioretinopathy. Am J Ophthalmol 151:303–309.e1PubMedCrossRef
102.
Sharma T, Shah N, Rao M, Gopal L, Shanmugam MP, Gopalakrishnan M, Bhende P, Bhende M, Shetty NS, Baluswamy S (2004) Visual outcome after discontinuation of corticosteroids in atypical severe central serous chorioretinopathy. Ophthalmology 111:1708–1714PubMedCrossRef
103.
Shin MC, Lim JW (2011) Concentration of cytokines in the aqueous humor of patients with central serous chorioretinopathy. Retina 31:1937–1943PubMedCrossRef
104.
Shinojima A, Hirose T, Mori R, Kawamura A, Yuzawa M (2010) Morphologic findings in acute central serous chorioretinopathy using spectral domain-optical coherence tomography with simultaneous angiography. Retina 30:193–202PubMedCrossRef
105.
Shinojima A, Sawa M, Sekiryu T, Oshima Y, Mori R, Hara C, Sugano Y, Kato A, Asato H, Yuzawa M et al (2017) A multicenter randomized controlled study of antioxidant supplementation with lutein for chronic central serous chorioretinopathy. Ophthalmologica 237:159–166. https://​doi.​org/​10.​1159/​000455807CrossRefPubMed
106.
Shulman S, Goldenberg D, Schwartz R, Habot-Wilner Z, Barak A, Ehrlich N, Loewenstein A, Goldstein M (2016) Oral Rifampin treatment for longstanding chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 254:15–22PubMedCrossRef
107.
Siedlecki J, Schworm B, Priglinger SG (2019) The pachychoroid disease spectrum-and the need for a uniform classification system. Ophthalmol Retina 3:1013–1015PubMedCrossRef
108.
Siegfried F, Rommel F, Rothe M, Brinkmann MP, Sochurek JAM, Freitag J, Grisanti S, Ranjbar M (2019) Evaluating diurnal changes in choroidal sublayer perfusion using optical coherence tomography angiography. Acta Ophthalmol 97:e1062–e1068PubMedCrossRef
109.
Spaide RF, Klancnik JM (2005) Fundus autofluorescence and central serous chorioretinopathy. Ophthalmology 112:825–833PubMedCrossRef
110.
Spaide RF, Campeas L, Haas A, Yannuzzi LA, Fisher YL, Guyer DR, Slakter JS, Sorenson JA, Orlock DA (1996a) Central serous chorioretinopathy in younger and older adults. Ophthalmology 103:2070–2079 (discussion 2079–2080)PubMedCrossRef
111.
Spaide RF, Hall L, Haas A, Campeas L, Yannuzzi LA, Fisher YL, Guyer DR, Slakter JS, Sorenson JA, Orlock DA (1996b) Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina 16:203–213PubMedCrossRef
112.
Spaide RF, Gemmy Cheung CM, Matsumoto H, Kishi S, Boon CJF, van Dijk EHC, Mauget-Faysse M, Behar-Cohen F, Hartnett ME, Sivaprasad S, Iida T, Brown DM, Chhablani J, Maloca PM (2021) Venous overload choroidopathy: A hypothetical framework for central serous chorioretinopathy and allied disorders. Prog Retin Eye Res. https://​doi.​org/​10.​1016/​j.​preteyeres.​2021.​100973CrossRefPubMed
113.
Spitznas M (1986) Pathogenesis of central serous retinopathy: a new working hypothesis. Graefes Arch Clin Exp Ophthalmol 224:321–324PubMedCrossRef
114.
Teke MY, Elgin U, Nalcacioglu-Yuksekkaya P, Sen E, Ozdal P, Ozturk F (2014) Comparison of autofluorescence and optical coherence tomography findings in acute and chronic central serous chorioretinopathy. Int J Ophthalmol 7:350–354PubMedPubMedCentral
115.
116.
Vasconcelos H, Marques I, Santos AR, Melo P, Pires I, Figueira J, de Abreu JF, Cachulo ML, Silva R (2013) Long-term chorioretinal changes after photodynamic therapy for chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 251(7):1697–1705PubMedCrossRef
117.
Venkatesh R, Pereira A, Jayadev C, Prabhu V, Aseem A, Jain K, Bavaharan B, Yadav NK, Chhablani J (2020) Oral eplerenone versus observation in the management of acute central serous chorioretinopathy: a prospective, randomized comparative study. Pharmaceuticals 13:170PubMedCentralCrossRef
118.
Verma L, Sinha R, Venkatesh P, Tewari H (2004) Comparative evaluation of diode laser versus argon laser photocoagulation in patients with central serous retinopathy: a pilot, randomized controlled trial [ISRCTN84128484]. BMC Ophthalmol 4:15PubMedPubMedCentralCrossRef
119.
Warrow DJ, Hoang QV, Freund KB (2013) Pachychoroid pigment epitheliopathy. Retina 33:1659–1672PubMedCrossRef
120.
Wolfensberger TJ, Chiang RK, Takeuchi A, Marmor MF (2000) Inhibition of membrane-bound carbonic anhydrase enhances subretinal fluid absorption and retinal adhesiveness. Graefes Arch Clin Exp Ophthalmol 238:76–80PubMedCrossRef
121.
Wong R, Chopdar A, Brown M (2004) Five to 15 year follow-up of resolved idiopathic central serous chorioretinopathy. Eye (Lond) 18:262–268CrossRef
122.
Wood EH, Karth PA, Sanislo SR, Moshfeghi DM, Palanker DV (2017) Nondamaging retinal laser therapy for treatment of central serous chorioretinopathy: what is the evidence? Retina 37:1021–1033PubMedCrossRef
123.
Wu ZHY, Lai RYK, Yip YWY, Chan WM, Lam DSC, Lai TYY (2011) Improvement in multifocal electroretinography after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy: a randomized placebo-controlled trial. Retina 31:1378–1386PubMedCrossRef
124.
Yalcinbayir O, Gelisken O, Akova-Budak B, Ozkaya G, Gorkem Cevik S, Yucel AA (2014) Correlation of spectral domain optical coherence tomography findings and visual acuity in central serous chorioretinopathy. Retina 34:705–712PubMedCrossRef
125.
126.
Yannuzzi LA, Shakin JL, Fisher YL, Altomonte MA (1984) Peripheral retinal detachments and retinal pigment epithelial atrophic tracts secondary to central serous pigment epitheliopathy. Ophthalmology 91:1554–1572PubMedCrossRef
127.
Yannuzzi LA, Slakter JS, Gross NE, Spaide RF, Costa DLL, Huang SJ, Klancnik JM, Aizman A (2003) Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina 23:288–298PubMedCrossRef
128.
Zhao M, Célérier I, Bousquet E, Jeanny J‑C, Jonet L, Savoldelli M, Offret O, Curan A, Farman N, Jaisser F et al (2012) Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest 122:2672–2679PubMedPubMedCentralCrossRef
129.
Zhao M, Zhang F, Chen Y, Dai H, Qu J, Dong C, Kang X, Liu Y, Yang L, Li Y et al (2015) A 50 % vs 30 % dose of verteporfin (photodynamic therapy) for acute central serous chorioretinopathy: one-year results of a randomized clinical trial. JAMA Ophthalmol 133:333PubMedCrossRef
Metadaten
Titel
Statement of the Professional Association of Ophthalmologists in Germany (BVA), the German Society of Ophthalmology (DOG) and the German Retina Society (RG) on central serous chorioretinopathy
Status 18 October 2021
verfasst von
Professional Association of German Ophthalmologists (Berufsverband der Augenärzte Deutschlands e. V., BVA)
German Society of Ophthalmology (Deutsche Ophthalmologische Gesellschaft, DOG)
German Retina Society e. V. (Retinologische Gesellschaft e. V., RG)
Publikationsdatum
06.04.2022
Verlag
Springer Medizin
Erschienen in
Die Ophthalmologie / Ausgabe Sonderheft 2/2022
Print ISSN: 2731-720X
Elektronische ISSN: 2731-7218
DOI
https://doi.org/10.1007/s00347-022-01614-6

Weitere Artikel der Sonderheft 2/2022

Die Ophthalmologie 2/2022 Zur Ausgabe

Erratum

Erratum zu: Epigenetische Veränderungen am Promotor des fragilen Histidin-Trias(FHIT)-Gens in menschlichen Sebozyten unter dem Einfluss der In-vitro-Kultur

Erratum

Erratum zu: Stellungnahme der Rechtskommission des BVA und der DOG zur augenärztlichen Beurteilung im Schwerbehindertenrecht und bei Blindheit

Erratum

Erratum zu: Unilaterale Netzhautblutungen bei Säuglingen – 2 Fälle von Schütteltrauma?

Erratum

Erratum zu: Stadiengerechte Therapie des Keratokonus

Leitthema

Surgical advancement in glaucoma during the past 10 years

Publisher Erratum

Erratum zu: Experimentelle Doktorarbeit in der Augenheilkunde

Neu im Fachgebiet Augenheilkunde

08.04.2024 | Therapieverfahren in der Augenheilkunde | CME

Ophthalmika in der Schwangerschaft

08.03.2024 | Vitrektomie | Originalien

Operative Therapie und Keimnachweis bei endogener Endophthalmitis
Datenauswertung aus 5 Augenkliniken

04.03.2024 | Vitrektomie | Leitthema

Bakterielle endogene Endophthalmitis
Erregerspektrum und medikamentöse Therapie

27.02.2024 | Erkrankungen der Hornhaut | CME

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen